Abstract
The prevalence of AKI was more than 6% prevalent in COVID-19 patients. Furthermore, AKI and hypertension were associated with higher morbidity and mortality. To control hypertension, there were different opinions and findings regarding the use of angiotensin receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACEIs); however, most of the studies suggested using these drugs to control blood pressure. AKI is associated with higher morbidity and mortality rates. A simple urinalysis in patients with suspected COVID-19 can reveal renal dysfunction at the earlier onset of complication, which may be very helpful before progressing to late-stage kidney disease. In addition to AKI, hypertension is considered to be accompanied by a worse prognosis. Further studies must be performed to clarify all the aspects of using hypertension medications in COVID-19 patients.